2-溴-5-碘苯甲酸 | 25252-00-0

• 物质功能分类: 有机原料 - 羧酸类化合物及衍生物
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-溴-5-碘苯甲酸
• 英文名称: 2-bromo-5-iodobenzoic acid
• CAS: 25252-00-0
• 化学式: C₇H₄BrIO₂
• mdl: MFCD00079716
• 分子量: 326.916
• InChiKey: QPKKBDSNZFSSOD-UHFFFAOYSA-N

物化性质

• 熔点：
  171-175 °C
• 沸点：
  371.2±32.0 °C(Predicted)
• 密度：
  2.331±0.06 g/cm3(Predicted)
• 溶解度：
  可溶于丙酮（少许）、DMSO（少许）、甲醇（少许）
• 稳定性/保质期：
  如果按照规格正确使用和储存，则不会分解。避免接触氧化物和光线。

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 安全说明：
  S26
• 危险品运输编号：
  NONH for all modes of transport
• WGK Germany：
  3
• 海关编码：
  2916399090
• 危险品标志：
  Xi
• 危险类别码：
  R36/37/38
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  保持贮藏器密封，并将其放入一个紧密封装的容器中。储存时，请确保放在阴凉、干燥的地方。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2-Bromo-5-iodobenzoic acid
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing

---

Section 3. Composition/information on ingredients.
Ingredient name: 2-Bromo-5-iodobenzoic acid
CAS number: 25252-00-0

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
Eye contact:
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels, refrigerated.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
No data
Boiling point:
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C7H4BrIO2
Molecular weight: 326.9

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, hydrogen bromide, hydrogen Iodide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-溴-5-碘苯甲酸 在 吡啶 、 三乙基硅烷 、 4-二甲氨基吡啶 、 aluminum (III) chloride 、 potassium phosphate 、 正丁基锂 、 草酰氯 、 lithium hydroxide monohydrate 、 三氟甲磺酸 、 三氟化硼乙醚 、 三氟乙酸 、 三环己基膦 作用下， 以 四氢呋喃 、 甲醇 、 正己烷 、 二氯甲烷 、 水 、 N,N-二甲基甲酰胺 、 甲苯 、 乙腈 为溶剂， 反应 25.17h， 生成 (2S,3R,4R,5S,6R)-2-(3-((2,3- dihydrobenzo[b][1,4]dioxin-6-yl)methyl)-4-ethylphenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol
  参考文献：
  名称：

  GLYCOSIDE DERIVATIVES AND USES THEREOF

  摘要：

  本发明提供了一种具有化学式I的化合物；一种制造本发明化合物的方法，以及其治疗用途。本发明还提供了一种药理活性剂的组合和制药组合物。

  公开号：

  US20120264700A1
• 作为产物：
  描述：

  2-溴苯甲酸 在 1,3-二碘-5,5-二甲基海因 、 硫酸 作用下， 以 二氯甲烷 为溶剂， 反应 2.0h， 以73.5%的产率得到2-溴-5-碘苯甲酸
  参考文献：
  名称：

  一种2-溴-5-碘苄醇的制备方法

  摘要：

  本发明公开了一种2‑溴‑5‑碘苄醇的制备方法，合成路线简单经典、操作简便、目标产物收率较高，且其中采用1,3‑二碘‑5,5‑二甲基海因作为碘化试剂，成本较低，是一条适合放大生产的方法。

  公开号：

  CN107954861A

文献信息

• [EN] DISUBSTITUTED OCTAHY-DROPYRROLO [3,4-C] PYRROLES AS OREXIN RECEPTOR MODULATORS<br/>[FR] OCTAHYDROPYRROLO [3,4-C] PYRROLES DISUBSTITUÉS UTILISÉS COMME MODULATEURS DU RÉCEPTEUR DE L'OREXINE
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2012145581A1

  公开（公告）日：2012-10-26

  Disubstituted octahydropyrrolo[3,4-c]pyrrole compounds are described, which are useful as orexin receptor modulators. Such compounds may be useful in pharmaceutical compositions and methods for the treatment of diseased states, disorders, and conditions mediated by orexin activity, such as insomnia.

  描述了二取代的八氢吡咯[3,4-c]吡咯化合物，这些化合物可用作促进睡眠素受体的调节剂。这些化合物可能在药物组合物和治疗由促进睡眠素活性介导的疾病状态、紊乱和病况的方法中有用，比如失眠。
• Regioselective Generation of Aryllithiums from Substituted Bromobenzenes XC6H4Br (X = 4-Br, 4-I, 4-CN, 2-CN)
  作者：Sergiusz Luliński、Janusz Serwatowski、Magdalena Szczerbińska

  DOI：10.1002/ejoc.200701126

  日期：2008.4

  Selected activated bromobenzenes XC6H4Br (X = 4-Br, 4-I, 4-CN, 2-CN) were successfully deprotonated with lithium 2,2,6,6-tetramethylpiperidide (LTMP) in THF at –80 °C. Thus, 2,5-dibromo-, 2-bromo-5-iodo-, 5-bromo-2-cyano-, and 3-bromo-2-cyanophenyllithium were obtained as stable intermediates and could be converted by subsequent reactions into various functionalized derivatives with good yields. A

  选定的活化溴苯 XC6H4Br (X = 4-Br, 4-I, 4-CN, 2-CN) 在 –80 °C 下在 THF 中用 2,2,6,6-四甲基哌啶锂 (LTMP) 成功去质子化。因此，获得了 2,5-二溴-、2-溴-5-碘-、5-溴-2-氰基-和 3-溴-2-氰基苯基锂作为稳定的中间体，并且可以通过后续反应转化为各种功能化的收益率良好的衍生品。讨论了溴与碘和氰基的定向效应的竞争。(© Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, Germany, 2008)
• Hepatitis C Virus Inhibitors
  申请人：Bachand Carol

  公开号：US20080044379A1

  公开（公告）日：2008-02-21

  The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

  本公开涉及化合物、组合物和治疗丙型肝炎病毒（HCV）感染的方法。还公开了含有这些化合物的药物组合物以及在治疗HCV感染中使用这些化合物的方法。
• [EN] HEPATITIS C VIRUS INHIBITORS<br/>[FR] INHIBITEURS DU VIRUS DE L'HÉPATITE C
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2009102318A1

  公开（公告）日：2009-08-20

  The present disclosure relates to (4-4' -diimidazolyl) biphenyls compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

  本公开涉及（4-4'-二咪唑基）联苯类化合物及用于治疗丙型肝炎病毒（HCV）感染的方法。还公开了含有这些化合物的药物组合物以及在治疗HCV感染中使用这些化合物的方法。
• [EN] TREATMENT OF METABOLIC DISORDERS IN EQUINE ANIMALS<br/>[FR] TRAITEMENT DE TROUBLES MÉTABOLIQUES CHEZ DES ÉQUIDÉS
  申请人：BOEHRINGER INGELHEIM VETMED

  公开号：WO2014161836A1

  公开（公告）日：2014-10-09

  The present invention relates to SGLT2 inhibitor or a pharmaceutically acceptable form thereof for use in the treatment and/or prevention of a metabolic disorder of an equine animal. In particular, the present invention relates the SGLT2 inhibitor or a pharmaceutically acceptable form thereof for use in the treatment and/or prevention of insulin resistance, hyperinsulinemia, impaired glucose tolerance, dyslipidemia, dysadipokinemia, subclinical inflammation, systemic inflammation, low grade systemic inflammation, obesity, and/or regional adiposity in an equine animal.

  本发明涉及SGLT2抑制剂或其药用可接受形式，用于治疗和/或预防马类动物的代谢紊乱。具体而言，本发明涉及SGLT2抑制剂或其药用可接受形式，用于治疗和/或预防马类动物的胰岛素抵抗、高胰岛素血症、糖耐量受损、血脂异常、脂联素异常、亚临床炎症、全身炎症、低级全身炎症、肥胖和/或局部脂肪堆积。